GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » PS Ratio

BCDA (BioCardia) PS Ratio : 59.09 (As of Mar. 24, 2025)


View and export this data going back to 1996. Start your Free Trial

What is BioCardia PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BioCardia's share price is $2.60. BioCardia's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.04. Hence, BioCardia's PS Ratio for today is 59.09.

The historical rank and industry rank for BioCardia's PS Ratio or its related term are showing as below:

BCDA' s PS Ratio Range Over the Past 10 Years
Min: 3.89   Med: 38.8   Max: 393.05
Current: 59.12

During the past 13 years, BioCardia's highest PS Ratio was 393.05. The lowest was 3.89. And the median was 38.80.

BCDA's PS Ratio is ranked worse than
80.87% of 993 companies
in the Biotechnology industry
Industry Median: 8.43 vs BCDA: 59.12

BioCardia's Revenue per Sharefor the three months ended in Sep. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.04.

Warning Sign:

BioCardia Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of BioCardia was -89.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 16.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -23.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was -19.70% per year.

During the past 13 years, BioCardia's highest 3-Year average Revenue per Share Growth Rate was 228.30% per year. The lowest was -49.70% per year. And the median was -8.15% per year.

Back to Basics: PS Ratio


BioCardia PS Ratio Historical Data

The historical data trend for BioCardia's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia PS Ratio Chart

BioCardia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.24 241.40 32.33 27.38 29.48

BioCardia Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.54 29.48 18.96 10.17 70.91

Competitive Comparison of BioCardia's PS Ratio

For the Biotechnology subindustry, BioCardia's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's PS Ratio distribution charts can be found below:

* The bar in red indicates where BioCardia's PS Ratio falls into.



BioCardia PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

BioCardia's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.60/0.044
=59.09

BioCardia's Share Price of today is $2.60.
BioCardia's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


BioCardia  (NAS:BCDA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


BioCardia PS Ratio Related Terms

Thank you for viewing the detailed overview of BioCardia's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCardia Business Description

Traded in Other Exchanges
N/A
Address
320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Executives
Simon H Stertzer director C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Peter Altman director, officer: President and CEO C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Edward M Gillis officer: Senior Vice President, Devices C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Bill Facteau director C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo director C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Andrew Scott Blank director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Jim L. Allen director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
David Mcclung officer: VP of Finance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Thomas Quertermous director C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Allan R Tessler director C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Richard T Allen officer: VP, Quality Assurance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070